Figure 1.
(a) Scatterplot showing a 12-month follow-up versus baseline logarithm of the minimal angle of resolution (logMAR) visual acuity after transitioning to aflibercept injections to treat recalcitrant neovascular age-related macular degeneration. (b) Scatterplot showing 12-month follow-up versus baseline central foveal thickness on SD-OCT (microns) after transitioning to aflibercept injections to treat recalcitrant neovascular age-related macular degeneration. (c) Scatterplot showing a 12-month follow-up versus baseline macular volume on SD-OCT (mm3) after transitioning to aflibercept injections to treat recalcitrant neovascular age-related macular degeneration.